This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) | MicrobiomeTrials
← Back to trials NCT07104032
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-06-12Est. Completion: 2027-12
Enrollment target: 132 participantsLocations Mayo Clinic Cancer Center, Phoenix, Arizona, United States HonorHealth Cancer Center, Scottsdale, Arizona, United States Providence Medical Foundation, Fullerton, California, United States UC Irvine Health, Orange, California, United States Yale Cancer Center, New Haven, Connecticut, United States Mayo Clinic Cancer Center, Jacksonville, Florida, United States Massachusetts General Hospital, Boston, Massachusetts, United States Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States Dana-Farber Cancer Institute, Boston, Massachusetts, United States Mayo Clinic Cancer Center, Rochester, Minnesota, United States Atlantic Health Overlook Medical Center, Summit, New Jersey, United States NYU Langone Health, New York, New York, United States Columbia University Irving Medical Center, New York, New York, United States Memorial Sloan Kettering Cancer Center, New York, New York, United States Duke University Medical Center, Durham, North Carolina, United States Providence Neurological Specialties West, Portland, Oregon, United States Other microbiome trials you might be interested in Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL) Diffuse Large B Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Mantle Cell Lymphoma (MCL) Marginal Zone Lymphoma (MZL) Waldenstrom Macroglobulinemia (WM) Primary Central Nervous System Lymphoma (PCNSL) Secondary Central Nervous System Lymphoma (SCNSL)
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activ…
Duarte, United States Est. completion Jan 2027
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Rhode Island Hospital, Providence, Rhode Island, United States Phase 1
Recruiting
Primary Central Nervous System Lymphoma
BACKGROUND:
* Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma.
* The outcome for patien…
Bethesda, United States Est. completion Sep 1, 2026